Biotech companies name new finance executives

Biodexa Pharmaceuticals, a publicly tradedclinical stage biopharma in the rare disease space, has promoted Fiona Sharp to CFO and company secretary, along with her election to the board of directors of the company. 

Fiona Sharp

Sharp joined Biodexa as group financial controller in December 2019. Prior to that, she was assistant director of finance for the Hywel Dda University Health Board, an organization with over 10,000 staff and a budget of approximately 800 million GBP.

In addition, Stephen Stamp will relinquish his roles as CFO and company secretary but remain as chief executive officer.

BioMarin Pharmaceutical appointed Rashmi Ramchandani as its vice president, chief accounting officer, effective January 19, 2026. Ramchandani also assumes the role of BioMarin’s principal accounting officer from Brian Mueller, executive vice president and CFO. Mueller will continue to serve as BioMarin’s executive vice president and CFO and principal financial officer.

Rashmi Ramchandan

Ramchandani has held various accounting and finance roles of increasing responsibility including Gilead Sciences, Strava, The Clorox Company, and McKesson Corporation. She started her career in public accounting with Deloitte and holds a BA in accounting and psychology from Illinois Wesleyan University. She is a CPA.

Crystalys Therapeutics, a clinical-stage biopharma developing therapeutic alternatives for the treatment of gout, has appointed Justin Thacker as its CFO. Most recently, Thacker was CFO of Capstan Therapeutics, where he helped guide the company through its acquisition by AbbVie, and Aristea Therapeutics, where he led core finance functions and IPO readiness. 

Justin Thacker

He has also held positions at Design Therapeutics, Synthorx (acquired by Sanofi), ACADIA Pharmaceuticals, Auspex Pharmaceuticals (acquired by Teva Pharmaceuticals), and Cadence Pharmaceuticals (acquired by Mallinckrodt). Thacker began his career with PricewaterhouseCoopers LLP and holds both a Master of Accountancy and a BS in accounting and general management from Kansas State University. He is a certified public accountant in the state of Missouri.

Obsidian Therapeutics, a clinical-stage biotech company in engineered cell and gene therapies, appointed Julie Feder as its chief financial officer (CFO). Feder brings over 20 years of finance experience in life sciences and healthcare. Her appointment is expected to elevate Obsidian’s clinical development of its lead engineered tumor-infiltrating (TIL) cell therapy, OBX-115, which is currently in Phase I and Phase II trials for melanoma and NSCLS, and Phase I/II in advanced solid tumors. 

Julie Feder

Feder was most recently CFO with Aura Biosciences, and prior to that, served as CFO at Verastem. She has also served as CFO for the Clinton Health Access Initiative, Inc., where she was responsible for managing a global team across multiple departments. Additionally, she developed the global finance strategy and oversaw internal audit, treasury, and global payroll functions. She was also a practicing CPA for 20 years and holds a BS in accounting from Yeshiva University’s School of Business.

Ocular Therapeutix has appointed Jason Robins as its interim CFO, where he will serve as the company’s principal financial officer and principal accounting officer. Robins is the senior vice president, finance, a role he has held since January 2025 and will perform his interim role as its CFO and COO, Donald Notman, is on temporary medical leave of absence. Ocular has clinical stage programs in Phase II and Phase III for sustained-release hydrogel therapies to treat eye diseases.

Jason Robins

Robins previously served as vice president, finance of Fusion Pharmaceuticals, a biopharmaceutical company acquired by AstraZeneca in June 2024. Robins received a BS from Babson College, an MS from the Harvard-MIT Division of Health Sciences and Technology, and an MBA from the MIT Sloan School of Management.

SpliceBio, a clinical-stage genetic medicines company using protein splicing to address diseases caused by mutations in large genes, has appointed Don Munoz as its CFO as the company shepherds its lead program, SB-007, through Phase I/II and beyond. Munoz most recently served as CFO of Aurion Biotech, where he helped lead the ocular cell therapy company’s acquisition by Alcon in March 2025. 

Donald Munoz

Previously, as CFO at NuCana, he led capital formation, partnering and financing strategy, including its $114 million initial public offering and $80 million follow-on offering. Munoz has also worked with Noxxon Pharma and has held senior leadership roles in investment banking with Cowen & Company, Leerink Partners, and Deutsche Bank. Munoz holds a BA from Dartmouth College and an MBA from Columbia Business School.

Zelluna, a biotech company publicly traded on the Oslo Stock Exchange, has appointed Geir Christian Melen as its new CFO, effective January 1, 2026. His predecessor, Hans Vassgård Eid, stepped down at the end of December 2025 and is supporting the transition. 

Geir Christian Melen

Melen was finance director for Zelluna for over seven years, bringing a strong familiarity with the company’s TCR-NK platform. This includes its lead program, ZI-MA4-1, targeting the MAGE-A4 tumor antigen, which is expected to enter clinical trials this year.

Melen brings experience in the Norwegian biotech space, including multiple CFO and CEO roles in both publicly listed and privately held companies. He has a MS in business administration from the Norwegian School of Economics. 

These announcements are from December 15, 2025, through January 26, 2026, as posted on BusinessWire, PRNewswire, Yahoo Finance, SEC documents, or company postings. If your company has an executive appointment announcement related to finance and accounting, please forward to Brandy Fidler at [email protected].